Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for healthcare industry professionals · Friday, June 25, 2021 · 544,736,722 Articles · 3+ Million Readers

Neutropenia Biologic Drug Treatment Companies Are Investing In Development Of Novel Drug Delivery Systems

Neutropenia Biologic Drug Treatment Market Report 2021: COVID-19 Growth And Change To 2030

Neutropenia Biologic Drug Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Neutropenia Biologic Drug Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, May 18, 2021 /EINPresswire.com/ -- Companies in the neutropenia biologic drug treatment market are increasingly investing in developing novel drug delivery systems to improve the therapeutic response of the drug and increase its efficacy. Novel drug delivery systems allow the delivery of a very high dose of drugs directly into the neutrophils, while the systemic dose remains low, thus disallowing side-effects. For instance, in August 2020, Asalyxa Bio announced its formation and seed funding to accelerate ASX-100 into first-in-human trials in 2021. ASX-100 is a novel spherical particle that releases a safe and effective anti-inflammatory agent, salicylic acid, directly to over-reactive immune cells, and is used for treating severe neutrophil-mediated disease.

Other neutropenia biologic drug treatment market trends include mergers and acquisitions. In February 2018, Partner Therapeutics, a Boston-based cancer company, acquired Leukine (Sargramostim) from Sanofi for $60 million. Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and it is indicated for the treatment of acute myelogenous leukemia (AML) in older adults both in allogeneic and autologous bone marrow transplantation. This acquisition provides a commercial business to Partner Therapeutics and also to make it a core component of the immune-oncology segment. Sanofi S.A. is a French multinational pharmaceutical company headquartered in Paris.

Major players in the neutropenia biologic drug treatment market are Teva Pharmaceutical, Amgen, Sanofi, Mylan, Kyowa Kirin, Baxter International, CVS Health Corp, Novartis, Spectrum Pharmaceuticals, and Partner Therapeutics.

Read More On The Global Neutropenia Biologic Drug Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatment-global-market-report-2020-30-covid-19-growth-and-change

The global neutropenia biologic drug treatment market is expected to grow from $11.55 billion in 2020 to $12.19 billion in 2021 at a compound annual growth rate (CAGR) of 5.5%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The neutropenia biologic drug treatment market is expected to reach $14.45 billion in 2025 at a CAGR of 4%.

The neutropenia biologic drug treatment market covered in this report is segmented by drug type into filgrastim, pegfilgrastim, lenograstim, lipegfilgrastim, sargramostim. The neutropenia biologic drug treatment market is also segmented by treatment type into antibiotic drugs, granulocyte-colony-stimulating factor (G-CSF), antifungal drugs, others and by distribution channel into retail pharmacies, hospital pharmacies, online pharmacies.

Neutropenia Biologic Drug Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides neutropenia biologic drug treatment global market overview, forecast neutropenia biologic drug treatment global market size and growth for the whole market, neutropenia biologic drug treatment global market segments, and geographies, neutropenia biologic drug treatment global market trends, neutropenia biologic drug treatment market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Neutropenia Biologic Drug Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3456&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

G-CSF (Granulocyte Colony Stimulating Factors) Market - By Type (Pegfilgrastim, Filgrastim, Lenograstim, Others), By Application (Oncology, Blood Disorders, Chronic and Autoimmune Disorders, Others), And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/granulocyte-colony-stimulating-factors-market

Blood Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Anemia And Other Blood Disorder Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn

Powered by EIN Presswire


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release